SLG
IOVA icon

Stanley-Laman Group’s Iovance Biotherapeutics IOVA Stock Holding History

Stanley-Laman Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-377,260
Closed -$4.24M – 276
2018
Q3 		$4.24M Buy
+377,260
New +$5.36M 1.04% 28

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stanley-Laman Group's IOVA Position: Q4 2018 in Review

Stanley-Laman Group sold out of Iovance Biotherapeutics (IOVA) in Q4 2018, closing a stake of 377,260 shares — an estimated $4.24M sold.

Stanley-Laman Group first reported a position in IOVA in Q3 2018 and held it in 1 quarter. The position peaked at $4.24M in Q3 2018. 139 funds tracked by Wall St. Rank hold IOVA as of Q4 2018.

  • Stanley-Laman Group reported no remaining Iovance Biotherapeutics position as of Q4 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 377,260 Iovance Biotherapeutics shares in Q4 2018, an estimated $4.24M.
  • Stanley-Laman Group first reported a position in Iovance Biotherapeutics in Q3 2018 and held it in 1 quarter.
  • Stanley-Laman Group's Iovance Biotherapeutics position peaked at $4.24M in Q3 2018.
  • 139 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2018.

Based on Stanley-Laman Group's 13F filing for Q4 2018, filed 7 Feb 2019.